Etravirine-based antiretroviral therapy in HIV/hepatitis C virus coinfected advanced fibrosis patients receiving triple therapy against hepatitis C virus with telaprevir

摘要

Telaprevir (TPV) is one of the hepatitis C virus (HCV) NS3/4A serine protease inhibitors recently approved for the treatment of patients with HCV genotype 1 both in naive and pretreated individuals [1,2]. To date, there is only one small phase 2 study on its safety and efficacy in HIV/HCV-coinfected patients naive to HCV therapy, with a proportion of cirrhotic less than 12% [3]. In this study, antiretroviral therapy (ART) was restricted to ATRIPLA or boosted atazanavir along with tenofovir with lamivudine or emtricitabine. Therefore, we lack information on the feasibility of protease inhibitor sparing highly-active antiretroviral therapy (HAART) other than efavirenz or raltegravir (RAL) [3,4]